Trial Profile

A Single-arm, Open-label, Multicenter, Phase II Study of AK105 in Patients With Metastatic Nasopharyngeal Carcinoma Who Have Progressed After At Least 2 Prior Lines of Chemotherapy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Apr 2025 According to Akeso Biopharma media release, based on AK105-304 & AK105-202 study, U.S. FDA has approved penpulimab-kcqx, in combination with cisplatin/carboplatin & gemcitabine for first-line treatment of adult recurrent/metastatic non-keratinizing nasopharyngeal carcinoma (NPC). FDA also approved penpulimab-kcqx as single agent for adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and with least one other prior line of therapy.
27 Feb 2025 Status changed from active, no longer recruiting to completed.
03 Jan 2024 Planned End Date changed from 31 Dec 2023 to 13 Apr 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com